Diabetes Roundup: Depression Increases Risk, Key Things to Know about Insulin Icodec

Greater Depression Severity Linked with Increased Diabetes Risk

Diabetes Roundup: Depression Increases Risk, Key Things to Know about Insulin Icodec / Sherry Young - stock.adobe.com

The severity of depression is positively correlated with the risk of diabetes and could be linked to different glycemic and metabolic markers, according to new research published in the journal Scientific Reports. Authors of the study said the findings highlight the importance of regularly monitoring diabetes parameters in patients with depression.

Q&A: Key Things Pharmacists Need to Know About Insulin Icodec

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, a professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences, sat down with Drug Topics to discuss how insulin icodec differs from existing daily basal insulins, important findings from the study, if the FDA’s decision will negatively impact patients with diabetes, and key things pharmacists need to know about the therapy.

Pharmacist-Led CGM Workflow Could Help Improve Diabetes Outcomes

A personal continuous glucose monitor (CGM) workflow led by a pharmacist could significantly improve outcomes in patients with diabetes, according to research published in the Journal of the American Pharmacists Association. The authors of the study said the findings demonstrate the importance of pharmacists in medical care teams.

Sotagliflozin’s Effect on BP Remains in T2D Regardless of Kidney Function | AHA 2024

The dual sodium-glucose cotransporter (SGLT) inhibitor sotagliflozin’s impact on systolic blood pressure is maintained in patients with type 2 diabetes (T2D) regardless of kidney function, according to research presented at the American Heart Association’s 2024 Scientific Sessions, held November 16 to 18 in Chicago, Illinois. The authors said the findings indicate that sotagliflozin could be a new therapeutic option for patients with diabetes.

Evaluating Empagliflozin’s Impact on Cardiovascular Outcomes in Patients with T2D | AHA 2024

The sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin could help improve clinical outcomes in patients who have type 2 diabetes (T2D) and cardiovascular disease, according to research data presented at the American Heart Association’s 2024 Scientific Sessions, held November 16 to 18 in Chicago, Illinois.

Eating Problems, Diabetes Distress Associated with Worse Time-in-Range | AHA 2024

Eating problems and diabetes distress are both significantly associated with worse time-in-range in patients with diabetes, according to data presented at the American Heart Association’s 2024 Scientific Sessions, held November 16 to 18 in Chicago, Illinois. Investigators said that targeted interventions could help patients achieve the recommended time-in-range.

Assessing SGLT-2 Inhibitors in Patients with T2D, Cardiovascular Complications | AHA 2024

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions, held November 16 to 18 in Chicago, Illinois looked deeper into the use of SGLT-2 inhibitors in patients with T2D and cardiovascular complications, examining SGLT-2 inhibitors following heart failure hospitalization, their impact on cardiorenal outcomes and in reducing the risk of all-cause mortality in patients with T2D and coronary artery disease.

READ MORE: Diabetes Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.